Buscar
01/09/2025
Hereditary transthyretin amyloidosis caused by the Val142Ile variant in Spain
de Frutos, F, Herrador, L, Peiró-Aventin, B, Eiros, R, Freire, JL, Zorio, E, Carbayo, A, Llongueras-Espi, P, Garcia-Alvarez, A, Ripoll-Vera, T, Macias, R, Vilches, S, Ruiz-Bustillo, S, Arana-Achaga, X, Ordás, JG, Piqueras-Flores, J, Ruiz-Cueto, M, Casasnovas, C, Tirón, C, Rojas-Garcia, R, Sevilla, T, Rodriguez-Palomares, JF, González-López, E, Villacorta, E, Garcia-Pavia, P, González-Costello, J. Hereditary transthyretin amyloidosis caused by the Val142Ile variant in Spain. REVISTA ESPANOLA DE CARDIOLOGIA. 2025; 78(9)DOI:10.1016/j.rec.2024.12.012. PMID:39827963. IF:4.900(Q1/2D).
01/09/2025
Correspondence to: Use of levodopa-carbidopa intestinal gel to treat patients with multiple system atrophy
Lopes, S, Fonseca, V, Pascual-Sedano, B, Simoes, R, Varanda, S, Pagonabarraga, J, Campolongo, A, Rodrigues, M. Correspondence to: Use of levodopa-carbidopa intestinal gel to treat patients with multiple system atrophy. PARKINSONISM & RELATED DISORDERS. 2025; 138DOI:10.1016/j.parkreldis.2025.107966. PMID:40763399. IF:3.400(Q2/3D).
01/09/2025
Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability
Veszelei, I, Godman, B, Aaltonen, K, Selke, GW, Garuoliene, K, Cangini, A, Kurdi, A, Rodrigues, AT, Pontes, C, Torre, C, Lunghi, C, Burton, E, Poplavska, E, Jónsdóttir, F, Petrova, G, Langner, I, Iaru, I, Odnoletkova, I, Slaby, J, Gvozdanovic, K, Saastamoinen, L, Laius, O, Benkö, R, Ziogaite, S, McTaggart, S, Mueller, T, de Pando, T, Tesar, T, Mitkova, Z, Wettermark, B. Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability. BIODRUGS. 2025; 39(5)DOI:10.1007/s40259-025-00732-2. PMID:40779010. IF:6.900(Q1/1D).
01/09/2025
Dimensions of insight in eating disorders: clinical and psychological predictors
Gawron, LP, Garrido-Ribas, I, Amaro-Carriba, MA, Hernández-Molina, M, Carceller-Sindreu, M, Carmona-Farrés, C, Portella, MJ, Pousa, E. Dimensions of insight in eating disorders: clinical and psychological predictors. PSYCHIATRY RESEARCH. 2025; 351DOI:10.1016/j.psychres.2025.116566. PMID:40482577. IF:3.900(Q1/2D).
01/09/2025
Adapting Barlow's Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Overweight Adults: A Nonrandomized Controlled Feasibility Study
Gawron, LP, Clifford, KR, Guillén, AR, Carceller-Sindreu, M, Farrés, CC, Bonnin, CD, Portella, MJ. Adapting Barlow's Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Overweight Adults: A Nonrandomized Controlled Feasibility Study. INTERNATIONAL JOURNAL OF EATING DISORDERS. 2025; 58(9)DOI:10.1002/eat.24474. PMID:40418102. IF:4.300(Q1/1D).
01/09/2025
Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic Treatments
Cendrós, M, Catalán, R, Torra, M, Penadés, R, González-Rodríguez, A, Brunet, M, Perez-Blanco, J, Cullell, N, Serra-Llovich, A, Hernandez, MH, Arranz, MJ. Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic Treatments. PHARMACOPSYCHIATRY. 2025; 58(05)DOI:10.1055/a-2603-0871. PMID:40527340. IF:2.200(Q3/6D).
01/09/2025
Occipital structure is linked to vagal tone in borderline personality but not in major depressive disorder
Camacho-Tellez, V, Castro, MN, De Pino, G, Duarte-Abritta, B, Wainsztein, AE, Herlyn, DL, Goldberg, X, Costanzo, EY, Cordoner, N, Menchón, JM, Soriano-Mas, C, Guinjoan, SM, Villarreal, MF. Occipital structure is linked to vagal tone in borderline personality but not in major depressive disorder. PSYCHIATRY RESEARCH-NEUROIMAGING. 2025; 352DOI:10.1016/j.pscychresns.2025.112044. PMID:40818358. IF:2.100(Q1/1D).
01/09/2025
Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease
Jessen, F, Arbizu, J, Boada, M, Balasa, M, Bennys, K, Boban, M, Bürger, K, Chincarini, A, Cagnin, A, De Deyn, PP, Düzel, E, Engelborghs, S, Ewers, M, Exalto, LG, van der Flier, WM, Fortea, J, Frederiksen, KS, Frisoni, GB, Frölich, L, Garza-Martinez, AJ, Grimmer, T, Hanseeuw, B, Hort, J, Ivanoiu, A, Kehoe, PG, Kennelly, SP, Kern, S, Klöppel, S, Krajcovicová, L, Kramberger, MG, McGuinness, B, Mecocci, P, Oberstein, TJ, Ousset, PJ, Paquet, C, Perneczky, R, Piazza, F, Plantone, D, Rainero, I, Sacco, G, Salm, E, Santana, I, Scarmeas, N, Schneider, A, Schott, JM, Solje, E, Stefanova, E, Stögmann, E, Strauss, M, Sutovsky, S, Waldemar, G, Winblad, B. Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease. JPAD-Journal of Prevention of Alzheimers Disease. 2025; 12(8)DOI:10.1016/j.tjpad.2025.100259. PMID:40640062. IF:7.800(Q1/1D).